This meeting is supported by:
POW24 - a face to face one day workshop prior to the start of the 2024
Open Meeting.
The current regulatory landscape for the development of peptide and
oligonucleotide drugs may lead companies to perform a variety of small
molecule focussed ADME studies in support of filing packages. The aim of
this workshop is for member company scientists to discuss and exchange ideas
and experience of peptide and oligonucleotide ADME related challenges
(active participation is expected). Addressing the question,
"if the current activities are suitable for these modalities, should
science-driven decisions on the development of such molecules be implemented
more in the industry"
If you work in the drug development of peptides and/or oligonucleotides, and
have such questions (or additional ones), please join the Workshop.
POW24 will start in the morning and run until early evening, after which we
will switch to networking mode in the true traditions of the DMDG.
The programme is in the making with the aspiration to provide talks touching
upon: targeting strategies beyond GalNAc, metabolism, distribution,
analytical challenges, modelling, and regulatory interactions.
If you have a hot topic you would like to be discussed (or a case story to
share) then please contact the organisers:
Steve Hood
(steve.r.hood@gsk.com)
Bo Lindmark
(bo.lindmark@astrazeneca.com)
Ralf Lotz
(ralf.lotz@boehringer-ingelheim.com)
Inga Björnsdottir
(inbj@novonordisk.com)
Jesper Kammersgaard Christensen
(jrci@novonordisk.com)
Come and be part of the peptide/oligo discussion!!!